Related Experiment Videos
Chemotherapeutic agents that induce mitochondrial apoptosis
Tadashi Asakura1, Kiyoshi Ohkawa
1Department of Biochemistry, Jikei University School of Medicine, Tokyo 105-8461, Japan. tad_asakura@jikei.ac.jp
Current Cancer Drug Targets
|December 8, 2004
Summary
Researchers modified anticancer agents to inhibit glutathione S-transferase P1-1 (GST P1-1), a protein linked to cancer growth and drug resistance. These modifications target the mitochondrial apoptotic pathway, offering new therapeutic strategies for cancer chemotherapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cancer chemotherapy requires agents targeting cell growth and apoptosis.
- The mitochondrial apoptotic pathway involves key proteins like c-Jun N-terminal kinase (JNK).
- Glutathione S-transferase P1-1 (GST P1-1) inhibits JNK and is implicated in carcinogenesis and multidrug resistance (MDR).
Purpose of the Study:
- To design novel anticancer agents that suppress GST P1-1 activity and expression.
- To explore therapeutic strategies targeting the mitochondrial apoptotic pathway.
Main Methods:
- Modification of existing anticancer agents.
- Focus on inhibiting GST P1-1 enzyme activity and expression.
- Investigating the role of the mitochondrial permeability transition pore in apoptosis.
Main Results:
- Demonstrated useful modifications of anticancer agents to suppress GST P1-1.
- Identified potential drugs, including proteasome inhibitors, to trigger mitochondrial permeability transition.
Conclusions:
- Targeting GST P1-1 offers a promising strategy in cancer chemotherapy.
- Modulating the mitochondrial apoptotic pathway, particularly the permeability transition pore, can induce cancer cell death.